Xinyuan Lei

Xinyuan Lei

Auto-generated profile, based on publicly available information

Xinyuan Lei

Department of Microbiology and Immunology, Stony Brook University, Stony Brook, NY, 11794, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZQZhijuan Qiu
Zhijuan Qiu
CKCamille Khairallah
Camille Khairallah
TCTimothy H. Chu
Timothy H. Chu
JIJessica N. Imperato
Jessica N. Imperato
XLXinyuan Lei
Xinyuan Lei
BSBrian Sheridan
Brian Sheridan
CD8 tissue-resident memory T (TRM) cells provide frontline protection at barrier tissues; however, mechanisms regulating TRM cell development are not completely understood. Priming dictates the migration of effector T cells to the tissue, while factors in the tissue induce in situ TRM cell differentiation. Whether priming also regulates in situ TRM cell differentiation uncoupled from migration is unclear. Here, we demonstrate that T cell priming in the mesenteric lymph nodes (MLN) regulates CD103+ TRM cell differentiation in the intestine. In contrast, T cells primed in the spleen were impaired in the ability to differentiate into CD103+ TRM cells after entry into the intestine. MLN priming initiated a CD103+ TRM cell gene signature and licensed rapid CD103+ TRM cell differentiation in response to factors in the intestine. Licensing was regulated by retinoic acid signaling and primarily driven by factors other than CCR9 expression and CCR9-mediated gut homing. Thus, the MLN is specialized to promote intestinal CD103+ CD8 TRM cell development by licensing in situ differentiation.

26 August 2025 in EMBO Reports
Verified
Journal Article
Open access
SDStephen D’AMico
Stephen D’AMico
VKVarvara Kirillov
Varvara Kirillov
JLJingxuan Liu
Jingxuan Liu
ZQZhijuan Qiu
Zhijuan Qiu
XLXinyuan Lei
Xinyuan Lei
NRNancy C Reich
Nancy C Reich
Oncogenic KRAS mutations underlie some of the deadliest human cancers. Genetic or pharmacological KRAS inactivation produces mixed outcomes and frequent relapse. Mechanisms of tumor resistance to KRAS inhibition remain poorly understood. We present evidence that STAT3 supports tumor growth following KRAS depletion. Using a conceptual framework of pancreatic ductal adenocarcinoma, we show that cancer cells that survive CRISPR-mediated ablation of mutant KRAS are dependent on STAT3 function to maintain tumorigenicity. Mechanistically, the combined loss of mutant KRAS and STAT3 disrupts a core transcriptional program of cancer cells critical to oncogenic competence. This in turn impairs tumor growth in mice and enhances immune rejection, leading to tumor clearance. We propose that the STAT3 transcriptional program operating in cancer cells enforces their malignant identity, rather than providing classical features of transformation, and shapes cancer persistence following KRAS inactivation. Our findings establish STAT3 as a critical enforcer of oncogenic identity in KRAS-ablated tumors, revealing a key vulnerability.